Residual vein thrombosis and onset of post-thrombotic syndrome: Influence of the 

4G/5G polymorphism of plasminogen activator inhibitor-1 gene by Incalcaterra, E. et al.
Thrombosis Research 133 (2014) 371–374
Contents lists available at ScienceDirect
Thrombosis Research
j ourna l homepage: www.e lsev ie r .com/ locate / th romresRegular ArticleResidual vein thrombosis and onset of post-thrombotic syndrome:
Inﬂuence of the 4G/5G polymorphism of plasminogen activator
inhibitor-1 geneEgle Incalcaterra ⁎, Francesco Meli, Ida Muratori, Egle Corrado, Corrado Amato,
Baldassare Canino, Filippo Ferrara
Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Via Del Vespro 127, 90129 PalermoAbbreviations: CEAP, clinical severity, etiology, anato
vein thrombosis; INR, international normalized ratio; OR,
activator inhibitor-1; PTS, post-thrombotic syndrome;
tissue-type plasminogen activator; u-PA, urokinase-type p
⁎ Corresponding author. Tel.: +39 916554408; fax: +3
E-mail address: e.incalcaterra@email.it (E. Incalcaterra
0049-3848/$ – see front matter © 2013 Published by Else
http://dx.doi.org/10.1016/j.thromres.2013.12.032a b s t r a c ta r t i c l e i n f oArticle history:
Received 3 September 2013
Received in revised form 8 December 2013
Accepted 28 December 2013
Available online 4 January 2014
Keywords:
Deep vein thrombosis
Plasminogen activator inhibitor 1
Sigle nuclear polymorphisms
Genetic polymorphisms
Fibrinolytic disorders
Anticoagulant agents
Background: Plasminogen activator inhibitor-1 (PAI-1) is the most important inhibitor of plasminogen activator.
The functional 4G/5G polymorphism of the gene coding for PAI-1may affect PAI-1 plasmatic activity, inﬂuencing
the imbalance between coagulation and ﬁbrinolysis cascades.
In this prospective cohort analytic study, we investigated the role of this single nucleotide polymorphism in the
persistence of thrombotic lesion and the occurrence of post-thrombotic syndrome.
Patients/Methods: In a group of 168 patients with post-surgical deep vein thrombosis of the legs, we analyzed the
4G/5G polymorphism in the promoter of PAI-1 gene and plasmatic PAI-1 activity.
Enrolled patients were divided in two groups: patients with 4G/5G polymorphism and increased PAI-1 activity
(n = 85) and patients without 4G/5G polymorphism and normal PAI-1 activity (n = 83). All patients were
treated according to current protocols and re-examined after 3, 12 and 36 months in order to evaluate the
persistence of thrombotic lesion and the occurrence of post-thrombotic syndrome.
Results:We found a signiﬁcantly increased PAI activity in carrier of the 4G allele, who experienced much more
frequently a persistence of thrombosis after 3, 12 and 36 months and/or the development of post-thrombosis
syndrome, in spite of the anticoagulant treatment.
Conclusions: These data not only conﬁrm the role playedby PAI-1 activity and by the4G/5GSNPof the PAI-1 gene,
but also suggest that current therapeutic protocols, recommending the administration of low weight molecular
heparin and oral anticoagulant for the treatment of deep vein thrombosis, could be non sufﬁcient for patients
genetically predisposed to a less efﬁcient clot lysis.© 2013 Published by Elsevier Ltd.Introduction
Plasminogen activator inhibitor-1 (PAI-1) is an acute phase protein
that is usually only expressed in adipocytes and endothelial cells, but
it can be highly expressed bymost cells in response to stress [1]. It reacts
with single and two-chain t-PA andwith two-chain u-PA inhibiting tar-
get proteinase by formation of a 1:1 stechiometric reversible complex;
the rapid inhibition of both t-PA and u-PA involves a reversible high-
afﬁnity between three negatively charged amino acids of PAI-1 and
highly positively charged regions in t-PA or in u-PA, binding to ﬁbrin
and inhibiting t-PA-mediated ﬁbrin dissolution. [2].my, patophysiology; DVT, deep
odds ratio; PAI-1, plasminogen
SD, standard deviation; t-PA,
lasminogen activator.
9 916554535.
).
vier Ltd.A functional polymorphism has been identiﬁed in the promoter
region of the gene coding for PAI-1 (the 4G/5G polymorphism) at the
-675 position. This variant affects plasma concentrations of PAI-1,
inﬂuencing the imbalance between coagulation and ﬁbrinolysis cas-
cades. The 4G allele is in fact associated with an increased transcription
of the gene and, subsequently, with increased levels of PAI-1 [3,4]. The
presence of the 4G allele, both in the heterozygotic and, especially, in
the homozygotic state, can induce a reduced ﬁbrinolytic activity, associ-
ated with thrombotic disorders in experimental models [5]. Discordant
studies have been recently published regarding the relationship be-
tween this polymorphism and the risk of arterial and/or venous throm-
boembolism in human, despite the results obtained in experimental
models [6–19].
Previouslywe have studied the extension of thrombotic lesions from
calf veins to popliteal and femoral veins in a group of patients with vein
thrombosis and found that carriers of the 4G allele experienced a more
marked extension than non carriers. In the group of patients with more
extensive thrombosis we also observed a reduced ﬁbrinolytic plasma
activity [20]. In this research we evaluated whether the presence of
Table 1
Baseline characteristics of carriers of the 4G allele by the advanced CEAP Classiﬁcation.
Patients (n)
12 C3s Ep Ad Po11,14
12 C3s Ep Ad Po 13,14
10 C3s Ep Ad Po11,13,14
10 C0s Ep Ad Po13,14
11 C0s Ep Ad Po11,14
12 C0s Ep Ad Po12,14
8 C1s Ep Ad Po11,14
10 C1s Ep Ad Po13,14
Table 3
Characteristics of carriers of the 4G allele by the advanced CEAP Classiﬁcation at the end of
the study.
Patients (n)
11 C4aS Es Ad Po11
11 C4aS Es Ad Po13
9 C4aS Es Ad Po11,14
10 C4aS Es Ad Po13,14
10 C4bS Es Ad Po11
10 C4bS Es Ad Po12,14
11 C1a Es Ad Pr11
13 C1a En An Pn13,14
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lesion and the occurrence of post-thrombotic syndrome in a group
of patients with post-surgical deep vein thrombosis in a prospective
36 months follow-up study.
Subjects and methods
From a total number of 1867 patients referred to the Department of
Angiology of the University Hospital of Palermo for the suspicion of a
deep vein thrombosis (DVT), we selected and enrolled, according to
the inclusion and exclusion criteria of the protocol, 168 consecutive
patients with post-surgical deep vein thrombosis (DVT) of the legs
documented by echo-Doppler.
The inclusion criteria were: presence of post-surgical thrombosis of
femoral and/or popliteal veins and age between 45 and 70 years.
The exclusion criteriawere: presence of a cancer,malignant haemato-
logical diseases, hyperhomocysteinemia, hyperviscosity syndromes or
the presence of antiphospholipid antibodies, the presence of factor V
Leiden or prothrombin 20210 G-Amutation and a clinical history of pre-
vious episodes of deep-venous thrombosis or of pulmonary embolism.
The presence of cancer was ruled-out by tumourmarkers dosage. Hyper-
homocysteinemia was diagnosed by the Medical Systems Immulite and
Immulite 1000 analyzers DPC – Diagnostic Products Corporation USA.
The Brookﬁeld viscosimeter at high and low shear rates was used to
exclude haemorheological disorders such as blood hyperscosity. Using
the Elisa test kit that provides a quantitative in vitro assay for human au-
toantibodies of the IgMor IgG class against cardiolipin in serum,we ruled
out patients with antiphospholipid antibodies: the upper limit of the
normal range (cut-off) was 12 Phospholipid-IgG or IgM-units/ml. Lastly,
the presence of the Factor V Leiden and the G20210A mutation for the
protrombin gene was excluded by means of the same method used for
4G/5G polymorphism.
In the enrolled patients we analyzed the PAI-1 promoter polymor-
phism 4G/5G using Nuclear Laser Medicine methods [21,22], which
included three steps: DNA isolation from fresh or frozen blood with
ethylenediaminetetracetate or citrate anticoagulant; PCR ampliﬁcation
using an Ampliﬁcation Mix containing biotinylated primers added to
Taq DNA Polymerase (1U) and DNA template (25-200 ng); hybridiza-
tion of ampliﬁcation products with a test strip containing allele-
speciﬁc oligonucleotide probes immobilized as an array of parallel
lines. The tests strips were inserted and incubated for 30 min at 45 °C
in a water-bath with shaking platform and subsequently two stringentTable 2
Baseline characteristics of non carriers of the 4G allele by the advancedCEAPClassiﬁcation.
Patients (n)
12 C3s Ep Ad Po11,14
11 C3s Ep Ad Po13,14
10 C3s Ep Ad Po11,13,14
11 C0s Ep Ad Po13,14
10 C0s Ep Ad Po11,14
10 C0s Ep Ad Po12,14
10 C1s Ep Ad Po11,14
9 C1s Ep Ad Po13,14washes at 45 °C were performed. For colour development 1 ml of
conjugate solution containing streptavidin-alkaline phosphatase was
added to the strip test and incubated in an orbital shaker at room
temperature for 15 min. Each strip was added to 1 ml of colour devel-
oper. After an incubation period of 15 min. at room temperature in
the dark, the genotype of the sample was determined.
We also studied plasmatic PAI-1 activity in all patients using the
Berichrom PAI method – Dade Behring Inc. Newark U.S.A. The principle
of this method is based on the deactivation of urokinase by PAI-1
contained in plasma. The remaining urokinase activity is determined
by the conversion of plasminogen into plasmin. The resulting plasmin
is measured by the segregation of a chromogen substrate at 405 nm
(concentration through plasminogenolysis). The destructive alfa2-
antiplasmin is deactivated through oxidation with chloramine T. In
healthy adults PAI-1 activity lay between 0.3 and 3.5 U/ml.
Patients with DVT were then divided in two different groups:
1. patients with 4G/5G polymorphism and increased PAI-1 activity
(n = 85, 48 males and 37 females), aged between 49 and 65 years
(mean age 56.96 ± 4.70 years);
2. patients without 4G/5G polymorphism and normal PAI-1 activity
(n = 83, 46 males and 34 females), aged between 47 and 68 years
(mean age 57.10 ± 5.54 years).
All the enrolled patients were treated daily with nadroparin calcium
anti-Xa at a dosage of 90 IU/kg body weight, given in two administra-
tions daily [23–25]. At the same time, sodium warfarin was initiated
and nadroparin administrated until the INR had stabilized (between 2
and 3). Heparin treatment was stopped in all patients after 5 or
6 days. The sodium warfarin treatment was prolonged for six months.
The adopted procedures were in agreement with theHelsinki Decla-
ration of 1975 as revised in 1983 andwere approved by the Ethic Coun-
cil of the Department of Internal Medicine of the University of Palermo.
All subjects gave their informed consent to participate to the study.
We performed a 36 months follow up, in all patients to evaluate the
persistence of thrombotic lesion (after 3 and 12 months) and the occur-
rence of post-thrombotic syndrome (after 36 months). The persistence
of thrombotic lesion and the occurrence of post thrombotic syndrome
was evaluated by B-mode real-time echo-color-doppler with amachine
ATLHDI 1500,Madison Co Ltd, Korea at three and twelvemonths and at
the end of the follow-up. Ultrasound examination was performed byTable 4
Characteristics of non carriers of the 4G allel by the advanced CEAP Classiﬁcation at the
end of the study.
Patients (n)
4 C4aS Es Ad Po11,14
6 C4aS Es Ad Po13
2 C4bS Es Ad Po13,14
2 C4bS Es Ad Po13
12 C1a Ep Ad Pr11
13 C1a Ep Ad Pr12
11 C1a En An Pn11,14
33 C1a En An Pn13,14
Table 5
Characteristics of the study population subdivided according to the genotype and persistence of thrombosis during the follow-up.
4G/4G (n 4) 4G/5G (n 81) 5G/5G (n 83) p
Age (years) 61,2 + 2,9 56,7 + 4,7 57,1 + 5,5 ns
Men/Women (n) 1/3 47/34 46/37 ns
Persistence after 3 months (%) 100 75,3 47 b 0,001
Persistence after 12 months (%) 100 71,6 21,7 b0,001
Persistence and development of PTS (%) after 36 months (%) 100 70,4 16,9 b0,001
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position and at a 45° angle. For each examined vein a compression
was performed by the probe, registering ﬂow changes. In order to
check the persistence of thrombotic lesion, the primary end-point was
the absence of compressibility of the vein wall, while the secondary
end-points were ﬂow velocity and colour distribution variations. We
also measured venous pressure in orthostatic position. During the
follow-up, patients were considered positive for persistence of throm-
bosis when they presented complete or partial thrombotic occlusion
in femoral or popliteal veins after 3 and 12 months. In order to evaluate
residual vein thrombosis, we measured and recorded major and minor
diameters of the venous segments before and after compression.
Ultra-sonography ﬁndings were arbitrarily scored as normalized when
residual thrombus occupied, after compression, less than 40% of the
vein area calculated in the absence of compression, utilizing the same
methodology used in previously published studies [26,27].
Moreover patients were considered positive for post-thrombotic
syndrome when they presented persistence of thrombosis and a vein
pressure value, in the supine position, N 90 mm Hg determined by
echocolordoppler at the level of posterior tibial vein associated with
pigmentation, varicose eczema or lipodermatosclerosis and atrophie
blanche. We determined the vein pressure by a tensiometric cuff
applied around the leg; we inﬂated the cuff until the 110 mm Hg,
then we deﬂated the cuff: the vein pressure value were relieved when
we listened to a sound as “a wind breath”.
Statistical analysis
Statistical analyses were performed using the SYSTAT DATA
software package, version 12 (Systat, San Jose, CA, USA). Continuous
variables normally distribuitedwere reported asmeans ± SD. Compar-
ison betweenmeanswere done using Student's t-test for unpaired data,
whereas comparison between frequencies were done using Chi-square
test. To investigate the association between the 4G/5G mutation and
persistence of thrombosis and/or development of post-thrombotic
syndrome logistic regression analysis was performed by calculating
odd ratios (OR) and 95% conﬁdence limits. The null hypothesis was
rejected at a two-tailed b0.05.
Results
Clinical characteristics of carriers and non carriers of the 4G allele at
the baseline of the study are shown in Tables 1 and 2. In the selected
population, composed 168 consecutive patients with post-surgical
DVT, 4 subjects were homozygous for the 4G allele, 81 were carrier of
the 4G/5G genotype and 83 of the 5G/5G genotype. After threemonths,
all patients who were homozygous for the 4G allele (100%) and 61 ofTable 6
PAI-1 activity distribution in the different genotypes.
4G/4G (n 4)
PAI-1 at baseline (U/ml) 5,22 + 0,08
PAI-1 after 3 months (U/ml) 5,12 + 0,14
PAI-1 after 12 months (U/ml) 5,10 + 0,13
PAI-1 after 36 months (U/ml) 4,99 + 0,11those who were eterozygous (75.3%) had a persistence of deep vein
thrombosis while among carrier of the 5G/5G genotype the frequency
of persistence was signiﬁcantly lower (39 patients, 47%; p b0.001).
This trend was conﬁrmed even in long term follow-up: 100% (n = 4)
of 4G/4G carriers and 71.6% (n = 58) of 4G/5G carries presented a per-
sistence of thrombosis after 12 months as well as 100% (n = 4) and
70.4% (n = 57) presented a persistence of thrombosis and a post-
thrombotic syndrome at the end of the study (after 36 months) com-
pared with the 21.7% (n = 18) and 16.9% (n = 14) of homozygous
for the wild type allele, respectively (p b 0.001 for both groups). The
clinical and anatomic sign’s changes between baseline and 36 months
follow-up are shown in Tables 3 and 4, respectively for carriers and
non carriers of the 4G allele.
Data about genotype distribution and persistence of thrombosis
after 3, 12 and 36 months and the development of post-thrombotic
syndrome are listed in Table 5.
Comparing PAI activity at baseline and after 3, 12 and 36 months
follow-up, a signiﬁcant difference was found between groups, being
PAI activity much more enhanced in carries of the 4G than 5G allele
(p b 0.001, Table 6).
Our results showed that 4G/5G polymorphism, causing an increased
PAI-1 activity, could have a very strong and signiﬁcant inﬂuence on the
persistence of thrombosis after short-term analysis and is associated
with an elevated incidence of post-thrombotic syndrome in the long
term follow-up.
Discussion
A decreased ﬁbrinolytic activity has been reported in several throm-
botic diseases, including arterial and venous thrombosis [28–31]. This
decrease has been related with increased levels of PAI activity and
with the presence of the 4G allele in young subjects with myocardial
infarction [3]. This polymorphism was thus considered a risk factor for
thrombotic disorders, even if these data have not been conﬁrmed in
other studies [32].
Several surveys have suggested that increased in vivo levels of PAI-1
promote ﬁbrin deposition. This deposition, associated with increased
PAI-1 expression, was observed in the aging-process and may contrib-
ute to the development of thrombosis. Sartori [33] and Stegnar [4] dem-
onstrated a PAI-1 induced hypoﬁbrinolysis, related to the presence of
the 4G allele among patients with deep vein thrombosis. To date,
there are no studies demonstrating a correlation between DVT onset
and persistence, 4G/5G polymorphism and a ﬁbrinolytic activity
decrease, in patients with increased levels of PAI-1.
Moreover, the role of the 4G/5G polymorphism in the pathogenesis
of DVT is not universally recognized. In a previous study we hypothe-
sized that the progression of thrombosis may be partially associated4G/5G (n 81) 5G/5G (n 83) p
4,12 + 0,89 1,29 + 0,66 b 0,001
4,17 + 0,89 1,29 + 0,65 b0,001
4,19 + 0,91 1,30 + 0,65 b0,001
4,17 + 0,93 1,31 + 0,65 b0,001
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phism and we showed an overall incidence of thrombosis progression
higher than other studies in which patients were not assessed for the
genetic proﬁle [20].
Taking into account that we excluded from this study patients with
the presence of factor V Leiden and/or G20210A prothrombinmutation,
we think that the persistence of thrombosis and the onset of post-
thrombotic syndrome could also be related to the reduced ﬁbrinolytic
activity related to the presence of 4G/5G polymorphism and to the in-
crease in PAI-1 activity. Moreover, in the presence of thrombotic vein
occlusion, theﬂowvelocity is very lownear to the thrombus.Webelieve
that this very low velocitymight favour the persistence and progression
of thrombotic lesions, especially in carriers of the 4G allele, because of a
reduced ﬁbrinolytic activity. However, our data cannot be considered
exhaustive because of the limited number of cases involved. Neverthe-
less, if these results will be conﬁrmed by further studies, they may
have clinical practice implications for the management and treatment
of venous thrombosis in carriers of the 4G polymorphism. It should be
in fact underlined that the 4G/5G polymorphism is not rare in the gen-
eral population, with a frequency of the heterozygous genotype ap-
proaching the normal genotype one, both in our survey and in several
published researches [20,34,35]. The use of the oral anticoagulant
seems to be inadequate in preventing the progression of thrombosis
in this population. For these reasons further preventive and therapeutic
strategies should be identiﬁed for the management of patients at high
risk of developing thrombosis and post-thrombotic syndrome and a
phamacogenetic approach could be proposed and should be validated
by large-scale studies.
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